pyrazines has been researched along with mycophenolic acid in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abdellatif, A; Achkar, K; Dilioglou, S; Gaber, AO; Jeroudi, A; Knight, R; Land, G; Patel, S; Raghavan, R; Suki, W | 1 |
| Cook, WJ; Elkins, S; Gaston, RS; Kumar, V; Prendergast, MB; Reddy, V; Sanders, PW | 1 |
| Everly, MJ; Terasaki, PI; Trivedi, HL | 1 |
| Li, Zw; Luo, M; Qiu, Jx; Wang, Y; Wen, Xf | 1 |
| Li, Y; Miao, Z; Pan, Q; Peppelenbosch, MP; Wang, Y; Yu, P | 1 |
| Chalermphunchai, N; Lelamali, K; Noppakun, K; Sawangduan, V; Sinpanee, T; Vongchaiudomchoke, T | 1 |
6 other study(ies) available for pyrazines and mycophenolic acid
| Article | Year |
|---|---|
Bortezomib in kidney transplant desensitization: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; B-Lymphocytes; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Histocompatibility Testing; HLA-A Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Mycophenolic Acid; Pyrazines; Rituximab; Waiting Lists | 2009 |
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin kappa-Chains; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Multiple Myeloma; Mycophenolic Acid; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Tacrolimus | 2009 |
Durability of antibody removal following proteasome inhibitor-based therapy.
Topics: Adult; Boronic Acids; Bortezomib; Calcineurin Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prognosis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Tissue Donors; Transplantation, Homologous | 2012 |
Effect of mycophenolic acid and bortezomib on purified human B cells: an in vitro study of long-term functionally stable MICA-sensitized renal recipients.
Topics: Aged; Antigens, CD19; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Cells, Cultured; Female; Histocompatibility Antigens Class I; Humans; Immunoglobulin M; In Vitro Techniques; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Proteasome Inhibitors; Pyrazines | 2013 |
2'-Fluoro-2'-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705.
Topics: Amides; Animals; Antiviral Agents; Caliciviridae Infections; Cell Line; Deoxycytidine; Humans; Mice; Mycophenolic Acid; Norovirus; Pyrazines; RAW 264.7 Cells; Ribavirin; Virus Replication | 2020 |
Modification of immunosuppressive agents in a kidney transplant recipient with COVID-19 and acute kidney injury.
Topics: Acute Kidney Injury; Adult; Amides; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Lopinavir; Male; Mycophenolic Acid; Pyrazines; Ritonavir; Steroids; Tacrolimus; Thailand; Transplant Recipients | 2021 |